|
Aug 1, 2010
By:
William Looney
It's back to the future in Pharm Exec's second-annual review of industry prospects in the IMS "Pharmerging 17"
|
Jul 30, 2010
By:
William Looney
To shed some light on China's potential, Pharm Exec sat down with Peter Young, President and Managing Partner of Young & Partners, who recently met with government and industry officials to review the investment and M&A climate for medicines.
|
Jul 8, 2010
By:
William Looney
As Europe sets the pace in slashing drug prices to meet austerity goals industry is seeking fresh ways to control the fallout. Will more dialogue be enough?
|
Jul 1, 2010
By:
William Looney
If there was ever a justification for endorsing a "triple bottom line" strategy for measuring Big Pharma's investment performance, it's the BP crisis.
|
Jun 1, 2010
By:
William Looney
The public-interest charity takes on pharma-influenced medicing and drug-resistant bacteria.
|
Jun 1, 2010
By:
William Looney
Innovation in industry has always required a strong internal champion; the danger is a process led by the risk-adverse and externally-driven stakeholder consensus called "death by faint praise." Is this really what we mean by "bold partnerships?"
|
|
Geno Germano, president of Pfizer's Specialty Care Business Unit, talks about how to win support in a sector that prizes connection with patients
May 11, 2010
By:
William Looney
Pfizer's Specialty Product Business Unit leader discusses his vision for the drug giant's specialty business; now the largest in the industry.
|
With recovery from the 2009 recession now underway, good deals are back on the drawing board. The challenge will be to paint over legacy risks and fill the canvas with the right mix of assets at the best price for long term shareholder gains
May 1, 2010
By:
William Looney
A panel of bankers and industry executives discuss what's ahead in deals for 2010.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
